ArticleBiochemistry and biophysics reports2026
Membrane-associated HDAC11: A potential new therapeutic targeting compartment in cancer cells.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone deacetylase 11 (HDAC11), the sole member of class IV histone deacetylases, has emerged as a novel and promising therapeutic target in cancer owing to its unique structural and enzymatic properties. Unlike other HDAC family members, HDAC11 exhibits predominant lysine defatty-acylase activity and has been implicated in tumor progression, immune regulation, and metastasis in a cancer type-dependent manner. However, the subcellular localization-specific targeting proteins for therapy have the advantage of minimized off-target and side effects. The localization of HDAC11 in cancer cells remains poorly understood. In this study, I investigated the localization of endogenous HDAC11 in breast cancer cells using biochemical subcellular fractionation. Consistent with previous reports, HDAC11 was detected in nuclear and cytoplasmic fractions. Unexpectedly, HDAC11 was also consistently detected in membrane-enriched fractions across the cell lines examined. This observation identifies a previously unrecognized membrane-associated pool of endogenous HDAC11 in cancer cells. The presence of HDAC11 within membrane fractions suggests potential non-canonical functions beyond epigenetic regulation. This finding could expand the current understanding of HDAC11 biology and provide a foundation for future studies aimed at defining its membrane-associated interactome, substrates, and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.